Farmacogenética, Genética del Cáncer, Polimorfismos Genéticos y Farmacoepidemiología
Karolinska Institute
Estocolmo, SueciaPublicaciones en colaboración con investigadores/as de Karolinska Institute (13)
2020
-
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes
Nature Genetics, Vol. 52, Núm. 1, pp. 56-73
2017
-
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer
Nature Genetics, Vol. 49, Núm. 5, pp. 680-691
2016
-
Genetic variants associated with antithyroid drug-induced agranulocytosis: A genome-wide association study in a European population
The Lancet Diabetes and Endocrinology, Vol. 4, Núm. 6, pp. 507-516
2013
2012
2011
-
ACTN3 R577X polymorphism does not influence explosive leg muscle power in elite volleyball players
Scandinavian Journal of Medicine and Science in Sports, Vol. 21, Núm. 6
2010
-
A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants
PLoS ONE, Vol. 5, Núm. 6
-
ACE and ACTN3 genes and muscle phenotypes in nonagenarians
International Journal of Sports Medicine, Vol. 31, Núm. 4, pp. 221-224
-
Are elite endurance athletes genetically predisposed to lower disease risk?
Physiological Genomics, Vol. 41, Núm. 1, pp. 82-90
-
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: Implications for risk prediction
Cancer Research, Vol. 70, Núm. 23, pp. 9742-9754
-
Is there an association between ACTN3 R577X polymorphism and muscle power phenotypes in young, non-athletic adults?
Scandinavian Journal of Medicine and Science in Sports, Vol. 20, Núm. 5, pp. 771-778
2009
-
Genotype distributions in top-level soccer players: A role for ace ?
International Journal of Sports Medicine, Vol. 30, Núm. 5, pp. 387-392
-
Is there an optimum endurance polygenic profile?
Journal of Physiology, Vol. 587, Núm. 7, pp. 1527-1534